ADAPY (Adaptimmune Therapeutics) Liabilities-to-Assets : 1.54 (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Adaptimmune Therapeutics Liabilities-to-Assets?

Adaptimmune Therapeutics ADAPY +5.80% Liabilities-to-Assets is 1.54 as of Jun. 2025.

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Adaptimmune Therapeutics's Total Liabilities for the quarter that ended in Jun. 2025 was $201.59 Mil. Adaptimmune Therapeutics's Total Assets for the quarter that ended in Jun. 2025 was $130.63 Mil. Therefore, Adaptimmune Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2025 was 1.54.

Adaptimmune Therapeutics  (OTCPK:ADAPY) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

Adaptimmune Therapeutics Liabilities-to-Assets Related Terms

Adaptimmune Therapeutics Liabilities-to-Assets Historical Data

* Premium members only.

The historical data trend for Adaptimmune Therapeutics's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptimmune Therapeutics Liabilities-to-Assets Chart

Adaptimmune Therapeutics Annual Data
Trend Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.24 0.56 0.75 0.86 0.95

Adaptimmune Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.70 0.75 0.95 1.24 1.54

ADAPY vs BCLI, APRE, JSPR: Liabilities-to-Assets Comparison

For the Biotechnology subindustry, Adaptimmune Therapeutics's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adaptimmune Therapeutics Liabilities-to-Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptimmune Therapeutics's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Adaptimmune Therapeutics's Liabilities-to-Assets falls into.


Adaptimmune Therapeutics Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Adaptimmune Therapeutics's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Liabilities-to-Assets (A: Dec. 2024 )=Total Liabilities/Total Assets
=234.114/245.963
=0.95

Adaptimmune Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2025 is calculated as

Liabilities-to-Assets (Q: Jun. 2025 )=Total Liabilities/Total Assets
=201.591/130.633
=1.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Liabilities-to-Assets →
What does a Liabilities-to-Assets of 1.54 mean?
Adaptimmune Therapeutics (ADAPY) has a Liabilities-to-Assets of 1.54 as of Jun. 2025. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Adaptimmune Therapeutics and its competitors.
Is Adaptimmune Therapeutics' Liabilities-to-Assets too high?
Adaptimmune Therapeutics' current Liabilities-to-Assets is 1.54.
How does Adaptimmune Therapeutics' Liabilities-to-Assets compare to BCLI and APRE?
Adaptimmune Therapeutics' Liabilities-to-Assets of 1.54 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Biotechnology company?
A good Liabilities-to-Assets depends on the Biotechnology industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Adaptimmune Therapeutics and its competitors. Adaptimmune Therapeutics's current Liabilities-to-Assets is 1.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptimmune Therapeutics stock overvalued right now?
Adaptimmune Therapeutics (ADAPY) has a current Liabilities-to-Assets of 1.54. The current Liabilities-to-Assets is 1.54. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Adaptimmune Therapeutics (ADAPY), the current Liabilities-to-Assets is 1.54 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adaptimmune Therapeutics Business Description

Other Exchanges 473A:Germany
Address 99 Park Drive, Milton Park, The Innovation Centre, Abingdon, Oxfordshire, GBR, OX14 4RY
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its product pipelines include ADP-600 [PRAME] and ADP-520 [CD70].